Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Their development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from them.

Sales of cancer drug Rubraca were higher than expected -- but so were the drugmaker's spending levels.

What's Behind Clovis Oncology's Mixed Q4 Results

Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q4 2019 Results - Earnings Call Transcript

Clovis (CLVS) delivered earnings and revenue surprises of -12.42% and 1.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Clovis Oncology (CLVS) Reports Q4 Loss, Tops Revenue Estimates

Sales of Rubraca are still up 30% year over year, but the growth was well short of the 50% pace the biotech set for the year.

Clovis Oncology's Sales Growth Slows in Q4

Investors are nervous heading into the company's fourth-quarter and full-year 2019 earnings report.

Here's Why Clovis Oncology Lost as Much as 11.8% Today

Is  (CLVS) Outperforming Other Medical Stocks This Year?

Is Clovis Oncology (CLVS) Outperforming Other Medical Stocks This Year?

Clovis' (CLVS) sole marketed drug, Rubraca, is likely to have driven revenues in the fourth quarter.

Is a Beat in the Cards for Clovis' (CLVS) Earnings in Q4?

Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.

Implied Volatility Surging for Clovis Oncology (CLVS) Stock Options

Clovis (CLVS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Clovis Oncology (CLVS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Eton Pharmaceuticals Inc

Immunomedics

Perrigo

vTv Therapeutics

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

3D Systems

Fulgent Genetics

Mallinckrodt PLC

By Harry Boxer, TheTechTrader Here are three health stocks and one technology stock that are at or near key breakout points:

4 Stocks Looking Higher During Earnings Season

Why Clovis Oncology Stock Is Popping Today

Atara Biotherapeutics

These two cancer stocks are trading at a pittance compared to their long-term value propositions.

2 Incredibly Cheap Cancer Stocks to Buy Now

Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.

Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review

Investors might be getting a little carried away with news from the FDA.

Here's Why Clovis Oncology Rose as Much as 25.6% Today

Clovis Oncology's struggling ovarian cancer therapy could become a new prostate cancer drug this spring.

FDA Gives Clovis Oncology's Rubraca a Priority Review

Shares of Clovis Oncology jumped in higher-than-average volume early Wednesday after U.S. regulators accepted the biotech company's application for a prostate cancer treatment.

Why This Highly Rated Biotech Stock Just Got A Double-Digit Jump

Clovis Oncology Inc (NASDAQ: CLVS) shares are advancing strongly after the company clinched a regulatory milestone with respect to its oncology drug Rubraca.

FDA Grants Priority Review Designation For Clovis Oncology's Rubraca Label Expansion

Shares of Clovis Oncology Inc. CLVS, +18.88% soared 22% in very active premarket trading Wednesday, after the biopharmaceutical company said the supplemental new drug application (sNDA) for its prostate cancer treatment Rubraca has been granted priority review status by the Food and Drug Administration.

Clovis Oncology's stock soars after FDA accepts sNDA for prostate cancer treatment

Antero Midstream Partners

Callon Petroleum

Gerdau

Paratek Pharma

Find Cheap Highly-Ranked Stocks Trading Under $10 for 2020

Amarin Corporation Plc

Bristol-Myers

Blackstone Group

Journey Medical Corp

Intuitive Surgical

Johnson & Johnson

Kaleido Biosciences Inc

Eli Lilly

Medtronic

Roche Holding AG

Sanofi

Sorrento Therapeutics Inc

The Super Bowl of healthcare kicked off early for these companies.

All the 2020 Pre-JPM News Healthcare Investors Need to Know

The pharmaceutical company's lead drug product continued to underwhelm. Just-released preliminary fourth-quarter results show much of the same.

Here's Why Clovis Oncology Stock Sank 41.9% in 2019

Clovis: Evaluating The Prospects Of A Possible Acquisition

Growth of the cancer drug has slowed, but an expanded approval could increase future sales.

Clovis Oncology Reports Preliminary Fourth Quarter Sales of Rubraca and Sells Additional Shares

Global Blood Therapeutics

These companies could kick off the year with big announcements and deliver gains to savvy investors.

News for Clovis Oncology Stock (CLVS)